<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03064854</url>
  </required_header>
  <id_info>
    <org_study_id>CPDR001C2101</org_study_id>
    <secondary_id>2016-002815-17</secondary_id>
    <nct_id>NCT03064854</nct_id>
  </id_info>
  <brief_title>PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients</brief_title>
  <official_title>Phase Ib, Multicenter, Open Label Study of PDR001 in Combination With Platinum Doublet Chemotherapy and Other Immunooncology Agents in PD-L1 Unselected, Metastatic NSCLS Patients (ElevatION:NSCLC-101 Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to establish the maximum tolerated dose (MTD) and/or
      recommended dose for expansion (RDE) of PDR001 when administered in combination with
      platinum-doublet chemotherapy and other immunooncology agent(s) in treatment naive patients
      with PD-L1 unselected, advanced NSCLC, and to estimate the preliminary anti-tumor activity in
      this patient population.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 24, 2017</start_date>
  <completion_date type="Anticipated">December 10, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 10, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Limiting Toxicities (DLTs) during the first 6 weeks of therapy</measure>
    <time_frame>42 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>every 6 weeks for up to 28 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS) per Investigator</measure>
    <time_frame>every 6 weeks for up to 28 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR) per Investigator</measure>
    <time_frame>every 6 weeks for up to 28 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) per Investigator</measure>
    <time_frame>every 6 weeks for up to 28 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response (TTR) per Investigator</measure>
    <time_frame>every 6 weeks for up to 28 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>from date of start of treatment to date of death due to any cause (up to 28 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Serum Concentration (Cmax) (PDR001)</measure>
    <time_frame>Day 1 of Cycle 1 and 4 of induction phase cycle = 21 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Plasma Concentration (Cmax) (chemotherapy)</measure>
    <time_frame>Day 1 of Cycle 1, 3 and 4; cycle = 21 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antidrug antibodies (ADA) prevalence at baseline</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ADA incidence on treatment</measure>
    <time_frame>Throughout study until 150 day safety follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Serum Concentration (Cmin) (PDR001)</measure>
    <time_frame>Day 1 of Cycle 1 to 4 of induction phase; Day 1 of Cycle 1 to 4, 6, 8 and every 6 cycle afterwards of maintenance phase; cycle = 21 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough PlasmaConcentration (Cmin) (chemotherapy)</measure>
    <time_frame>Day 1 of Cycle 1, 3 and 4; Cycle = 21 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PDF) by blinded independend review commitee (BIRC)</measure>
    <time_frame>every 6 weeks for up to 28 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR) by blinded independend review commitee (BIRC)</measure>
    <time_frame>every 6 weeks for up to 28 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR) by blinded independend review commitee (BIRC)</measure>
    <time_frame>every 6 weeks for up to 28 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) by blinded independend review commitee (BIRC)</measure>
    <time_frame>every 6 weeks for up to 28 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response (TTR) by blinded independend review commitee (BIRC)</measure>
    <time_frame>every 6 weeks for up to 28 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of AEs (CTCAE v4.03)</measure>
    <time_frame>through study completion, an average of one year</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">114</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Group A: squamous, gem/cis+PDR001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B: non-squamous, pem/cis+PDR001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C: paclitaxel/carbo+PDR001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group E: non-squamous, pem/cis (or carbo)+PDR001+canakinumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PDR001</intervention_name>
    <description>Powder for solution for infusion</description>
    <arm_group_label>Group A: squamous, gem/cis+PDR001</arm_group_label>
    <arm_group_label>Group B: non-squamous, pem/cis+PDR001</arm_group_label>
    <arm_group_label>Group C: paclitaxel/carbo+PDR001</arm_group_label>
    <arm_group_label>Group E: non-squamous, pem/cis (or carbo)+PDR001+canakinumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Intravenous infusion</description>
    <arm_group_label>Group A: squamous, gem/cis+PDR001</arm_group_label>
    <arm_group_label>Group B: non-squamous, pem/cis+PDR001</arm_group_label>
    <arm_group_label>Group E: non-squamous, pem/cis (or carbo)+PDR001+canakinumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Intravenous infusion</description>
    <arm_group_label>Group A: squamous, gem/cis+PDR001</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>Intravenous infusion</description>
    <arm_group_label>Group B: non-squamous, pem/cis+PDR001</arm_group_label>
    <arm_group_label>Group E: non-squamous, pem/cis (or carbo)+PDR001+canakinumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Intravenous infusion</description>
    <arm_group_label>Group C: paclitaxel/carbo+PDR001</arm_group_label>
    <arm_group_label>Group E: non-squamous, pem/cis (or carbo)+PDR001+canakinumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Intravenous infusion</description>
    <arm_group_label>Group C: paclitaxel/carbo+PDR001</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Canakinumab</intervention_name>
    <description>Subcutaneous injection</description>
    <arm_group_label>Group E: non-squamous, pem/cis (or carbo)+PDR001+canakinumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          1. Patient has stage IIIB (and is not a candidate for definitive multimodality therapy)
             or has stage IV NSCLC or relapsed locally advanced or metastatic NSCLC as follows:

               1. Group A, group B and group C only: Patients not previously treated with any
                  systemic anti-cancer therapy (e.g. cytotoxic drugs, targeted therapy, monoclonal
                  antibody therapy including immunotherapy (e.g. PD-1/PD-L1 inhibitors) or targeted
                  therapies, either experimental or not), with exception of neo-adjuvant or
                  adjuvant therapy as depicted in inclusion criterion 4.

               2. Group D only: Patients who have received only one prior systemic therapy
                  treatment consisting of a PD-1 and/or PD-L1 inhibitor with or without a CTLA4
                  inhibitor for NSCLC, with exception of neo-adjuvant or adjuvant therapy as
                  depicted in inclusion criterion 4. The last dose of prior immunotherapy must have
                  been administered at least 6 weeks prior to the start of study treatment (cycle 1
                  day 1).

          2. Histologically or cytologically confirmed diagnosis of NSCLC that is EGFR Wild-type,
             ALK-negative rearrangement and ROS1-negative rearrangement

          3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1

          4. Patients with at least 1 measurable tumor lesion as assessed by Computed Tomography
             (CT) Scan or Magnetic Resonance Imaging (MRI) according to RECIST 1.1.

        Main Exclusion Criteria:

          1. Patient with a history of severe hypersensitivity reaction to the planned study
             treatment including gemcitabine, paclitaxel, cisplatin, carboplatin, pemetrexed or any
             known excipients of these drugs

          2. History of severe hypersensitivity reactions to other monoclonal antibodies, which in
             the opinion of the investigator may pose an increased risk of serious infusion
             reaction.

          3. Patient has history of interstitial lung disease or interstitial pneumonitis,
             including clinically significant radiation pneumonitis (i.e., affecting activities of
             daily living or requiring therapeutic intervention).

          4. History of leptomeningeal metastases

          5. Active, known or suspected autoimmune disease or a documented history of autoimmune
             disease, including ulcerative colitis and Crohn's disease (Patients with vitiligo,
             type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only
             requiring hormone replacement, psoriasis not requiring systemic treatment, or
             conditions not expected to recur in the absence of an external trigger are permitted
             to enroll).

          6. Use of any live vaccines against infectious diseases within 4 weeks of initiation of
             study treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Highlands Oncology Group</name>
      <address>
        <city>Fayetteville</city>
        <state>Arkansas</state>
        <zip>72703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA Santa Monica Hematology / Oncology SC-2</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford Cancer Center SC</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System SC</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine SC</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center SC</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roeselare</city>
        <zip>8800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Praha 4</city>
        <zip>140 59</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lyon Cedex</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Marseille cedex 05</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gottingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Koeln</city>
        <zip>51109</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pokfulam</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Meldola</city>
        <state>FC</state>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rozzano</city>
        <state>MI</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Aviano</city>
        <state>PN</state>
        <zip>33081</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Koto ku</city>
        <state>Tokyo</state>
        <zip>135 8550</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>February 6, 2017</study_first_submitted>
  <study_first_submitted_qc>February 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 27, 2017</study_first_posted>
  <last_update_submitted>August 15, 2019</last_update_submitted>
  <last_update_submitted_qc>August 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PDR001</keyword>
  <keyword>immunotherapy</keyword>
  <keyword>Non-small cell lung cancer</keyword>
  <keyword>lung</keyword>
  <keyword>NSCLC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

